Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

March 3, 2023

https://www.globenewswire.com/news-release/2023/03/03/2620152/0/en/Incannex-Engages-Catalent-for-Development-and-cGMP-Manufacture-of-Psilocybin-Drug-Product-for-Clinical-Trials-and-Potential-Commercial-Use.html

Highlights:

MELBOURNE, Australia, March 03, 2023 (GLOBE NEWSWIRE) — Incannex Healthcare Limited (Nasdaq:IXHL) (ASX:IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Catalent (‘Catalent’) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development program and (2), potential wider commercial use.

Read more at globenewswire.com

Related news for (IXHL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.